<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204594</url>
  </required_header>
  <id_info>
    <org_study_id>rM28-001</org_study_id>
    <nct_id>NCT00204594</nct_id>
  </id_info>
  <brief_title>Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28</brief_title>
  <official_title>Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II clinical trial to analyze safety and efficiency of intralesional application of
      the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic
      melanoma stage III/IV and unresectable metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I/II clinical trial to analyze safety and efficiency of intralesional application of
      the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic
      melanoma stage III/IV and unresectable metastasis. The antibody is directed against epitops
      of human CD28 and the melanoma associated surface antigen HMV-MAA. Treatment over 5 days with
      dose escalation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical response</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rM28</intervention_name>
    <arm_group_label>Antibody</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous PBMCs</intervention_name>
    <arm_group_label>Antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  malignant melanoma stage III/IV

          -  injectable soft tissue metastasis

          -  informed consent given

          -  Karnofsky &gt;= 70%

        Exclusion Criteria:

          -  additional chemotherapeutical treatment

          -  systemic glucocorticoids

          -  brain metestasis

          -  other malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garbe Claus, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of dermatology, university of tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gundram Jung, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tuebingen, Dept. of Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Tuebingen, Department of dermatology</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Thomas Eigentler</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <keyword>mRNA</keyword>
  <keyword>vaccination</keyword>
  <keyword>melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

